🚀 VC round data is live in beta, check it out!
Mira Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Mira Pharmaceuticals and similar public comparables like Ascelia Pharma, Intervacc, RenovoRx, Atara Biotherapeutics and more.
Mira Pharmaceuticals Overview
About Mira Pharmaceuticals
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Founded
2020
HQ
Employees
5
Website
Financials (FY)
EV
$41M
Mira Pharmaceuticals Financials
Mira Pharmaceuticals reported last fiscal year revenue of — and negative EBITDA of ($10M).
In the same fiscal year, Mira Pharmaceuticals generated ($10M) in EBITDA losses and had net loss of ($10M).
Revenue (LTM)
Mira Pharmaceuticals P&L
In the most recent fiscal year, Mira Pharmaceuticals reported revenue of — and EBITDA of ($10M).
Mira Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($10M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($10M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Mira Pharmaceuticals Stock Performance
Mira Pharmaceuticals has current market cap of $45M, and enterprise value of $41M.
Market Cap Evolution
Mira Pharmaceuticals' stock price is $1.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41M | $45M | 1.4% | XXX | XXX | XXX | $-0.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMira Pharmaceuticals Valuation Multiples
Mira Pharmaceuticals trades at (3.9x) EV/EBITDA.
Mira Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Mira Pharmaceuticals has market cap of $45M and EV of $41M.
Equity research analysts estimate Mira Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mira Pharmaceuticals has a P/E ratio of (4.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $45M | XXX | $45M | XXX | XXX | XXX |
| EV (current) | $41M | XXX | $41M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (3.9x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (3.9x) | XXX | XXX | XXX |
| P/E | — | XXX | (4.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (8.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Mira Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Mira Pharmaceuticals Margins & Growth Rates
Mira Pharmaceuticals' revenue in the last fiscal year grew by —.
Mira Pharmaceuticals' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $2.1M for the same period.
Mira Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 31% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $2.1M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Mira Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mira Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascelia Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Intervacc | XXX | XXX | XXX | XXX | XXX | XXX |
| RenovoRx | XXX | XXX | XXX | XXX | XXX | XXX |
| Atara Biotherapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mira Pharmaceuticals M&A Activity
Mira Pharmaceuticals acquired XXX companies to date.
Last acquisition by Mira Pharmaceuticals was on XXXXXXXX, XXXXX. Mira Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Mira Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMira Pharmaceuticals Investment Activity
Mira Pharmaceuticals invested in XXX companies to date.
Mira Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Mira Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Mira Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Mira Pharmaceuticals
| When was Mira Pharmaceuticals founded? | Mira Pharmaceuticals was founded in 2020. |
| Where is Mira Pharmaceuticals headquartered? | Mira Pharmaceuticals is headquartered in United States. |
| How many employees does Mira Pharmaceuticals have? | As of today, Mira Pharmaceuticals has over 5 employees. |
| Who is the CEO of Mira Pharmaceuticals? | Mira Pharmaceuticals' CEO is Erez Aminov. |
| Is Mira Pharmaceuticals publicly listed? | Yes, Mira Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Mira Pharmaceuticals? | Mira Pharmaceuticals trades under MIRA ticker. |
| When did Mira Pharmaceuticals go public? | Mira Pharmaceuticals went public in 2023. |
| Who are competitors of Mira Pharmaceuticals? | Mira Pharmaceuticals main competitors are Ascelia Pharma, Intervacc, RenovoRx, Atara Biotherapeutics. |
| What is the current market cap of Mira Pharmaceuticals? | Mira Pharmaceuticals' current market cap is $45M. |
| Is Mira Pharmaceuticals profitable? | No, Mira Pharmaceuticals is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.